SynthesisJournal of advanced research2025
Advances in statin adverse reactions and the potential mechanisms: A systematic review.
Synthesis in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- A novel exopolysaccharide fromGut microbes · 2026Article
- Effects of Hedan Tablets Combined With Simvastatin on Hyperlipidemia: Insights From Microbiomics and Metabolomics.Biomedical chromatography : BMC · 2026Article
- Comparative Effects of Different Statin Regimens on Postoperative Outcomes in Isolated Coronary Artery Bypass Grafting: A Propensity Score-Matched Analysis.Journal of clinical medicine · 2026Article
- Octacosanol: A Natural Bioactive Ingredient for Atherosclerosis Prevention and Cardiovascular Health Promotion.Molecules (Basel, Switzerland) · 2026Review
- Postharvest Aging and Harvest Stage Shape the Bioactive Profile, Hypolipidemic Activity, and Gut Microbiota-Modulating Effects of Citrus Peel Extracts in High-Fat-Diet-Fed Mice.Foods (Basel, Switzerland) · 2026Article
- Differential associations of lipid profile and genetic susceptibility with sleep duration.Lipids in health and disease · 2026Article
- Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm.Medicina (Kaunas, Lithuania) · 2026Review
- Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.The pharmacogenomics journal · 2026Review
- Article
- Predictive value of the Naples Prognostic Score for rapid kidney function decline in stage 3-4 CKD: a multicenter study.Scientific reports · 2026Article
- Circulating Liver-Enriched miR-122 in COVID-19 Patients: A Longitudinal Real-Life Study.International journal of molecular sciences · 2026Article
- DERA-Catalyzed Chemoenzymatic Access to Nucleobase-Substituted Candidate Statin Precursors.Biomolecules · 2026Article
- Biomaterials Promote the Regression of Atherosclerotic Plaque by Regulating Cell Behavior.International journal of nanomedicine · 2026Review
- Rosuvastatin Versus Atorvastatin for Cardiovascular Disease Risk in Patients with Type 2 Diabetes: A Korean Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effects ofJournal of Taibah University Medical Sciences · 2025Article
- Atorvastatin Induces Bioenergetic Impairment and Oxidative Stress Through Reverse Electron Transport.Antioxidants (Basel, Switzerland) · 2025Article
- Dyslipidemia Treatment in Patients with Acute Coronary Syndrome: Is It Time to Move to Combination Therapy?Journal of clinical medicine · 2025Review
- Natural Product-Derived Drugs: Structural Insights into Their Biological Mechanisms.Biomolecules · 2025Review
- Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence.Pharmacy (Basel, Switzerland) · 2025Article
- A Bibliometric Analysis of Strategies for Atherosclerosis Treatment with Organic Nanoparticles.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElevated low-density lipoprotein (LDL) cholesterol is a major risk factor for cardiovascular disease. Statins are the cornerstone of preventing and treating cardiovascular disease and can reduce LDL cholesterol by more than 60%. Although statins have high tolerability and safety, as the number of users increases, their adverse reactions in the liver, kidneys, skeletal muscles, and their potential to induce diabetes have also received widespread attention. AIM OF REVIEW: How to maximize the lipid-lowering effect of statins, reduce the incidence of adverse reactions, promote the rational application of statins in the clinic, and improve the risk-benefit level, in order to benefit more cardiovascular patients and provide reference for the related basic research of statins. Key scientific concepts of review: This article provides a comprehensive review of the clinical manifestations of statin-related adverse reactions (associated myopathy, hepatotoxicity, nephrotoxicity, glycemic effects, central nervous system, hemorrhagic stroke, etc.), risk factors for triggering adverse reactions, statin interactions with other drugs (food), potential etiopathological mechanisms and common interventions in the clinic. Genetic diversity is strongly associated with statin adverse effects, and thus, in the future genetic testing may also be key to mitigating statin adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.